Document is current
Any future updates will be listed below
-
Authors
Matsuoka, Katsuyoshi
Motoya, Satoshi
Yamamoto, Takayuki
Matsuura, Minoru
Fujii, Toshimitsu
Shinzaki, Shinichiro
Mikami, Yohei
Arai, Shoko https://orcid.org/0000-0003-4609-1609
Oshima, Junichi
Endo, Yutaka
Yuasa, Hirotoshi
Hoshi, Masato
Sato, Keiko
Hisamatsu, Tadakazu
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03643211 at ClinicalTrials.govDocuments that mention this clinical trial
Post-marketing surveillance of tofacitinib in patients with ulcerative colitis in Japan: a final report of safety and effectiveness data
https://doi.org/10.1007/s00535-025-02249-5
-
Funding
Funding for this research was provided by:
Pfizer
- License Information
-
More Information
Article History
Received: 6 October 2024
Accepted: 3 April 2025
First Online: 21 April 2025
Declarations
:
: K.M. has received research grants from AbbVie, EA Pharma, JIMRO, Kissei, Mitsubishi Tanabe, Mochida, Nippon Kayaku, and Zeria, and speaking fees from AbbVie, EA Pharma, Eli Lilly, Gilead Sciences, Janssen, JIMRO, Kissei, Kyorin, Mitsubishi Tanabe, Mochida, Nippon Kayaku, Pfizer Inc, and Zeria. S.M. has received research grants from AbbVie, Ajinomoto, AstraZeneca, Janssen, and Pfizer Inc, and speaker’s bureau from Mitsubishi Tanabe. T.Y. has received lecture fees from AbbVie, Celltrion, EA Pharma, Gilead Sciences, Janssen, JIMRO, Kissei, Kyorin, Mitsubishi Tanabe, Mochida, Nippon Kayaku, Pfizer Inc, and Takeda. M.M. has received lecture fees from AbbVie and Janssen. T.F. has received research grants from AbbVie, Alfresa, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, EA Pharma, Eisai, Eli Lilly, Gilead Sciences, Janssen, Kissei, Mebix, Sanofi, and Takeda, and speaking fees from AbbVie, Ajinomoto Pharma, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, EA Pharma, Eisai, Janssen, Kissei, Kyorin, Kyowa Hakko Kirin, Mitsubishi Tanabe, Mochida, Nichi-Iko, Nippon Kayaku, Pfizer Inc, Taiho, Takeda, and Zeria. S.S. has received grants from AbbVie, EA Pharma, JIMRO, Kyorin, Mochida, Nippon Kayaku, and Zeria, consulting fees from AbbVie, EA Pharma, Eli Lilly, Gilead Sciences, Janssen, Kissei, Sekisui Medical, and Takeda, and lecture fees from AbbVie, EA Pharma, Gilead Sciences, Janssen, JIMRO, Kissei, Kyorin, Mitsubishi Tanabe, Mochida, Nippon Kayaku, Pfizer Inc, Sekisui, and Takeda. Y.M. has no conflicts to disclose. S.A. is an employee and stockholder of Pfizer, Japan. J.O. is an employee of Pfizer R&D, Japan. Y.E. is an employee and stockholder of Pfizer R&D, Japan. H.Y. is an employee and stockholder of Pfizer R&D, Japan. M.H. is an employee and stockholder of Pfizer, Japan. K.S. is an employee of Pfizer R&D, Japan. T.H. has received grants from AbbVie, Boston Scientific, EA Pharma, JIMRO, Kissei, Kyorin, Mitsubishi Tanabe, Mochida, Nippon Kayaku, Pfizer Inc, Takeda, and Zeria, consulting fees from AbbVie, Bristol Myers Squibb, EA Pharma, Eli Lilly, Gilead Sciences, Janssen, Mitsubishi Tanabe, Nichi-Iko, and Pfizer Inc, and lecture fees from AbbVie, EA Pharma, Janssen, JIMRO, Kissei, Kyorin, Mitsubishi Tanabe, Mochida, Pfizer Inc, and Takeda.
